

Two Binding Sites for [³H]PBR28 in Human Imaging of Neuroinflammation

Journal of Cerebral Blood Flow and Metabolism

30, 1608-1618

DOI: [10.1038/jcbfm.2010.63](https://doi.org/10.1038/jcbfm.2010.63)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Translocator protein (18 kDa) (TSPO) as a therapeutic target for neurological and psychiatric disorders. <i>Nature Reviews Drug Discovery</i> , 2010, 9, 971-988.	21.5	774
3	Imaging of Atherosclerosis. <i>Annual Review of Medicine</i> , 2011, 62, 25-40.	5.0	101
4	Evaluation of Novel <i>N</i> ¹ -Methyl-2-phenylindol-3-ylglyoxylamides as a New Chemotype of 18 kDa Translocator Protein-Selective Ligand Suitable for the Development of Positron Emission Tomography Radioligands. <i>Journal of Medicinal Chemistry</i> , 2011, 54, 366-373.	2.9	25
5	Age and disease related changes in the translocator protein (TSPO) system in the human brain: Positron emission tomography measurements with [¹¹ C]vinpocetine. <i>NeuroImage</i> , 2011, 56, 1111-1121.	2.1	80
6	Quantitation of Translocator Protein Binding in Human Brain with the Novel Radioligand [¹⁸ F]-FEPPA and Positron Emission Tomography. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2011, 31, 1807-1816.	2.4	98
7	Comparison of ¹⁸ F- and ¹¹ C-labeled aryloxyanilide analogs to measure translocator protein in human brain using positron emission tomography. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2011, 38, 352-357.	3.3	33
8	Biodistribution and radiation dosimetry of the 18 kDa translocator protein (TSPO) radioligand [¹⁸ F]FEDAA1106: a human whole-body PET study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2011, 38, 2058-2065.	3.3	29
9	Translocator Protein PET Imaging for Glial Activation in Multiple Sclerosis. <i>Journal of NeuroImmune Pharmacology</i> , 2011, 6, 354-361.	2.1	98
10	Imaging Brain Microglial Activation Using Positron Emission Tomography and Translocator Protein-Specific Radioligands. <i>International Review of Neurobiology</i> , 2011, 101, 19-39.	0.9	75
11	Towards molecular imaging of multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2011, 17, 262-272.	1.4	11
12	The Translocator Protein. <i>Journal of Nuclear Medicine</i> , 2011, 52, 677-680.	2.8	139
13	Imaging of Microglia Activation in Stroke. <i>Stroke</i> , 2011, 42, 507-512.	1.0	111
14	Mixed-Affinity Binding in Humans with 18-kDa Translocator Protein Ligands. <i>Journal of Nuclear Medicine</i> , 2011, 52, 24-32.	2.8	330
15	Translocator Protein (18 kDa) Polymorphism (rs6971) Explains <i>in-vivo</i> Brain Binding Affinity of the PET Radioligand [¹⁸ F]-FEPPA. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2012, 32, 968-972.	2.4	131
16	Radiation Dosimetry and Biodistribution of the TSPO Ligand ¹¹ C-DPA-713 in Humans. <i>Journal of Nuclear Medicine</i> , 2012, 53, 330-335.	2.8	23
17	Increased In Vivo Expression of an Inflammatory Marker in Temporal Lobe Epilepsy. <i>Journal of Nuclear Medicine</i> , 2012, 53, 234-240.	2.8	90
18	Is there Any Correlation Between Binding and Functional Effects at the Translocator Protein (TSPO) (18 kDa)? <i>Current Molecular Medicine</i> , 2012, 12, 387-397.	0.6	0
19	An 18-kDa Translocator Protein (TSPO) Polymorphism Explains Differences in Binding Affinity of the PET Radioligand PBR28. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2012, 32, 1-5.	2.4	642

#	ARTICLE	IF	CITATIONS
20	Imaging of microglia in patients with neurodegenerative disorders. <i>Frontiers in Pharmacology</i> , 2012, 3, 96.	1.6	98
21	A microPET study of the regional distribution of [¹¹ C]-PK11195 binding following temporary focal cerebral ischemia in the rat. Correlation with post mortem mapping of microglia activation. <i>NeuroImage</i> , 2012, 59, 2007-2016.	2.1	30
22	Identifying improved TSPO PET imaging probes through biomathematics: The impact of multiple TSPO binding sites in vivo. <i>NeuroImage</i> , 2012, 60, 902-910.	2.1	73
23	Visualising Neuroinflammation in Post-Stroke Patients: A Comparative PET Study with the TSPO Molecular Imaging Biomarkers [¹¹ C]PK11195 and [¹¹ C]vinpocetine. <i>Current Radiopharmaceuticals</i> , 2012, 5, 19-28.	0.3	41
24	The translocator protein ligand [18F]DPA-714 images glioma and activated microglia in vivo. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2012, 39, 811-823.	3.3	80
25	Synthesis of fluorine-18-labelled TSPO ligands for imaging neuroinflammation with Positron Emission Tomography. <i>Journal of Fluorine Chemistry</i> , 2012, 134, 107-114.	0.9	19
26	Current paradigm of the 18-kDa translocator protein (TSPO) as a molecular target for PET imaging in neuroinflammation and neurodegenerative diseases. <i>Insights Into Imaging</i> , 2012, 3, 111-119.	1.6	115
27	Molecular imaging of microglia/macrophages in the brain. <i>Glia</i> , 2013, 61, 10-23.	2.5	160
28	Structure-activity relationships of novel iodinated quinoline-2-carboxamides for targeting the translocator protein. <i>MedChemComm</i> , 2013, 4, 1461.	3.5	13
29	Whole Body Biodistribution and Radiation Dosimetry in Humans of a New PET Ligand, [18F]-FEPPA, to Image Translocator Protein (18 kDa). <i>Molecular Imaging and Biology</i> , 2013, 15, 353-359.	1.3	23
30	Quantification of the Specific Translocator Protein Signal of ¹⁸ F-PBR111 in Healthy Humans: A Genetic Polymorphism Effect on In Vivo Binding. <i>Journal of Nuclear Medicine</i> , 2013, 54, 1915-1923.	2.8	105
31	Synthesis and Structure-Activity Relationships of 5,6,7-Substituted Pyrazolopyrimidines: Discovery of a Novel TSPO PET Ligand for Cancer Imaging. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 3429-3433.	2.9	42
32	A Genetic Polymorphism for Translocator Protein 18 Kda Affects both <i>in Vitro</i> and <i>in Vivo</i> Radioligand Binding in Human Brain to this Putative Biomarker of Neuroinflammation. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2013, 33, 53-58.	2.4	207
33	Stratified medicine in psychiatry: a worrying example or new opportunity in the treatment of anxiety?. <i>Journal of Psychopharmacology</i> , 2013, 27, 119-122.	2.0	16
34	Influence of <i>TSPO</i> Genotype on ¹¹ C-PBR28 Standardized Uptake Values. <i>Journal of Nuclear Medicine</i> , 2013, 54, 1320-1322.	2.8	56
35	Are prescribed benzodiazepines likely to affect the availability of the 18 kDa translocator protein (TSPO) in PET studies?. <i>Synapse</i> , 2013, 67, 909-912.	0.6	21
36	Determination of [¹¹ C]PBR28 Binding Potential <i>in vivo</i> : A First Human TSPO Blocking Study. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2014, 34, 989-994.	2.4	117
37	The translocator protein as a drug target in Alzheimer's disease. <i>Expert Review of Neurotherapeutics</i> , 2014, 14, 439-448.	1.4	20

#	ARTICLE	IF	CITATIONS
38	Quantitative imaging of neuroinflammation in human white matter: A positron emission tomography study with translocator protein 18 kDa radioligand, [¹⁸ F]â€FEPPA. Synapse, 2014, 68, 536-547.	0.6	17
39	Synthesis and evaluation of new ¹⁸ F-labelled acetamidobenzoxazolone-based radioligands for imaging of the translocator protein (18 kDa, TSPO) in the brain. Organic and Biomolecular Chemistry, 2014, 12, 9621-9630.	1.5	29
40	Neuroinflammation in healthy aging: A PET study using a novel Translocator Protein 18kDa (TSPO) radioligand, [18F]-FEPPA. NeuroImage, 2014, 84, 868-875.	2.1	56
41	Preparation and evaluation of novel pyrazolo[1,5-a]pyrimidine acetamides, closely related to DPA-714, as potent ligands for imaging the TSPO 18kDa with PET. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 1550-1556.	1.0	38
42	Investigating the interactions of the 18kDa translocator protein and its ligand PK11195 in planar lipid bilayers. Biochimica Et Biophysica Acta - Biomembranes, 2014, 1838, 1019-1030.	1.4	38
43	Immunological Mechanisms and Therapies in Brain Injuries and Stroke. , 2014, , .		4
44	[¹⁸ F]DPAâ€C5yne, a novel fluorineâ€18â€labeled analogue of DPAâ€714: radiosynthesis and preliminary evaluation as a radiotracer for imaging neuroinflammation with PET. Journal of Labelled Compounds and Radiopharmaceuticals, 2014, 57, 410-418.	0.5	11
45	Cocaine Abuse in Humans Is Not Associated with Increased Microglial Activation: An 18-kDa Translocator Protein Positron Emission Tomography Imaging Study with [11C]PBR28. Journal of Neuroscience, 2014, 34, 9945-9950.	1.7	55
46	In Vivo Assessment of Brain White Matter Inflammation in Multiple Sclerosis with ¹⁸ F-PBR111 PET. Journal of Nuclear Medicine, 2014, 55, 1112-1118.	2.8	82
47	Development of <i>N</i> -Methyl-(2-arylquinolin-4-yl)oxypropanamides as Leads to PET Radioligands for Translocator Protein (18 kDa). Journal of Medicinal Chemistry, 2014, 57, 6240-6251.	2.9	21
48	Synthesis and Evaluation of Translocator 18 kDa Protein (TSPO) Positron Emission Tomography (PET) Radioligands with Low Binding Sensitivity to Human Single Nucleotide Polymorphism rs6971. ACS Chemical Neuroscience, 2014, 5, 963-971.	1.7	91
49	Tracking neuroinflammation in Alzheimerâ€™s disease: the role of positron emission tomography imaging. Journal of Neuroinflammation, 2014, 11, 120.	3.1	89
50	Promising potential of new generation translocator protein tracers providing enhanced contrast of arthritis imaging by positron emission tomography in a rat model of arthritis. Arthritis Research and Therapy, 2014, 16, R70.	1.6	32
51	Utility of 18â€F-FDG and 11C-PBR28 microPET for the assessment of rat aortic aneurysm inflammation. EJNMMI Research, 2014, 4, 20.	1.1	15
52	The impact of the rs6971 polymorphism in TSPO for quantification and study design. Clinical and Translational Imaging, 2015, 3, 417-422.	1.1	28
53	TSPO imaging in stroke: from animal models to human subjects. Clinical and Translational Imaging, 2015, 3, 423-435.	1.1	14
54	Mapping neuroinflammation in frontotemporal dementia with molecular PET imaging. Journal of Neuroinflammation, 2015, 12, 108.	3.1	51
55	Improved Automated Radiosynthesis of [11C]PBR28. Scientia Pharmaceutica, 2015, 83, 413-427.	0.7	7

#	ARTICLE	IF	CITATIONS
56	Imaging neuroinflammation in Alzheimer's disease and other dementias: Recent advances and future directions. <i>Alzheimer's and Dementia</i> , 2015, 11, 1110-1120.	0.4	66
57	Effect of the myeloperoxidase inhibitor AZD3241 on microglia: a PET study in Parkinson's disease. <i>Brain</i> , 2015, 138, 2687-2700.	3.7	168
58	Ether analogues of DPA-714 with subnanomolar affinity for the translocator protein (TSPO). <i>European Journal of Medicinal Chemistry</i> , 2015, 93, 392-400.	2.6	14
59	Optimized Quantification of Translocator Protein Radioligand ¹⁸ F-DPA-714 Uptake in the Brain of Genotyped Healthy Volunteers. <i>Journal of Nuclear Medicine</i> , 2015, 56, 1048-1054.	2.8	56
60	In-vivo imaging of grey and white matter neuroinflammation in Alzheimer's disease: a positron emission tomography study with a novel radioligand, [18F]-FEPPA. <i>Molecular Psychiatry</i> , 2015, 20, 1579-1587.	4.1	101
61	Roles of microglia in brain development, tissue maintenance and repair. <i>Brain</i> , 2015, 138, 1138-1159.	3.7	316
62	Evaluation of [11C]CB184 for imaging and quantification of TSPO overexpression in a rat model of herpes encephalitis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 1106-1118.	3.3	14
63	¹¹ C-PBR28 imaging in multiple sclerosis patients and healthy controls: test-retest reproducibility and focal visualization of active white matter areas. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 1081-1092.	3.3	77
64	Radiosynthesis and in vivo evaluation of two imidazopyridineacetamides, [11C]CB184 and [11C]CB190, as a PET tracer for 18 kDa translocator protein: direct comparison with [11C](R)-PK11195. <i>Annals of Nuclear Medicine</i> , 2015, 29, 325-335.	1.2	17
65	Positron-emission tomography molecular imaging of glia and myelin in drug discovery for multiple sclerosis. <i>Expert Opinion on Drug Discovery</i> , 2015, 10, 557-570.	2.5	27
66	Positron emission tomography imaging of the 18-kDa translocator protein (TSPO) with [18F]FEMPA in Alzheimer's disease patients and control subjects. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 438-446.	3.3	64
67	Pharmacokinetic Analysis of ¹¹ C-PBR28 in the Rat Model of Herpes Encephalitis: Comparison with ¹¹ C-PK11195. <i>Journal of Nuclear Medicine</i> , 2016, 57, 785-791.	2.8	21
68	Concise Review: Cell Therapies for Stroke and Traumatic Brain Injury: Targeting Microglia. <i>Stem Cells</i> , 2016, 34, 537-542.	1.4	26
69	Neuroimaging Biomarkers in Alzheimer's Disease. , 2016, , 51-100.		8
71	PET Neurochemical Imaging Modes. <i>Seminars in Nuclear Medicine</i> , 2016, 46, 20-27.	2.5	21
72	Changes in Binding of [123I]CLINDE, a High-Affinity Translocator Protein 18 kDa (TSPO) Selective Radioligand in a Rat Model of Traumatic Brain Injury. <i>NeuroMolecular Medicine</i> , 2016, 18, 158-169.	1.8	18
73	In Vivo Imaging of Human Neuroinflammation. <i>ACS Chemical Neuroscience</i> , 2016, 7, 470-483.	1.7	165
74	Evaluation of PET Imaging Performance of the TSPO Radioligand [18F]DPA-714 in Mouse and Rat Models of Cancer and Inflammation. <i>Molecular Imaging and Biology</i> , 2016, 18, 127-134.	1.3	12

#	ARTICLE	IF	CITATIONS
75	Quantitative longitudinal imaging of activated microglia as a marker of inflammation in the pilocarpine rat model of epilepsy using [¹¹ C]-(<i>R</i>)-PK11195 PET and MRI. Journal of Cerebral Blood Flow and Metabolism, 2017, 37, 1251-1263.	2.4	24
76	Molecular imaging to track Parkinson's disease and atypical parkinsonisms: New imaging frontiers. Movement Disorders, 2017, 32, 181-192.	2.2	88
77	Microglial activation in Parkinson's disease using [18F]-FEPPA. Journal of Neuroinflammation, 2017, 14, 8.	3.1	88
78	Neuroinflammation in Neurodegenerative Disorders—a Review. Current Neurology and Neuroscience Reports, 2017, 17, 25.	2.0	240
79	Brain translocator protein occupancy by ONO-2952 in healthy adults: A Phase 1 PET study using [¹¹ C]PBR28. Synapse, 2017, 71, e21970.	0.6	7
80	Imaging in Parkinson's Disease. International Review of Neurobiology, 2017, 132, 233-274.	0.9	21
81	Microglial positron emission tomography (PET) imaging in epilepsy: Applications, opportunities and pitfalls. Seizure: the Journal of the British Epilepsy Association, 2017, 44, 42-47.	0.9	28
82	Pro-inflammatory activation of primary microglia and macrophages increases 18-kDa translocator protein expression in rodents but not humans. Journal of Cerebral Blood Flow and Metabolism, 2017, 37, 2679-2690.	2.4	153
83	Positron emission tomography in amyotrophic lateral sclerosis: Towards targeting of molecular pathological hallmarks. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 533-547.	3.3	7
84	Two populations of TSPO binding sites in oral cancer SCC-15 cells. Experimental Cell Research, 2017, 350, 279-283.	1.2	3
85	PET imaging of the neurovascular interface in cerebrovascular disease. Nature Reviews Neurology, 2017, 13, 676-688.	4.9	38
86	TSPO PET for glioma imaging using the novel ligand 18F-GE-180: first results in patients with glioblastoma. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 2230-2238.	3.3	91
87	<i>TSPO</i> mutations in rats and a human polymorphism impair the rate of steroid synthesis. Biochemical Journal, 2017, 474, 3985-3999.	1.7	80
88	[¹¹ C]-ER176, a Radioligand for 18-kDa Translocator Protein, Has Adequate Sensitivity to Robustly Image All Three Affinity Genotypes in Human Brain. Journal of Nuclear Medicine, 2017, 58, 320-325.	2.8	146
89	Determination and reduction of translocator protein (TSPO) ligand rs6971 discrimination. MedChemComm, 2017, 8, 202-210.	3.5	12
90	Imaging Microglial Activation in Untreated First-Episode Psychosis: A PET Study With [¹⁸ F]FEPPA. American Journal of Psychiatry, 2017, 174, 118-124.	4.0	103
91	Water Homeostasis Dysfunctions and Edema in Neuroinflammatory Disease. , 2017, , 337-352.		0
92	The emerging role of PET imaging in dementia. F1000Research, 2017, 6, 1830.	0.8	43

#	ARTICLE	IF	CITATIONS
93	TSPO PET with [18F]GE-180 sensitively detects focal neuroinflammation in patients with relapsingâ€“remitting multiple sclerosis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 1423-1431.	3.3	53
94	Head-to-Head Comparison of ¹¹ C-PBR28 and ¹⁸ F-GE180 for Quantification of the Translocator Protein in the Human Brain. <i>Journal of Nuclear Medicine</i> , 2018, 59, 1260-1266.	2.8	48
95	Update on Molecular Imaging in Parkinsonâ€™s Disease. <i>Neuroscience Bulletin</i> , 2018, 34, 330-340.	1.5	19
96	Sifting through the surfeit of neuroinflammation tracers. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2018, 38, 204-224.	2.4	92
97	Translocator Protein as an Imaging Marker of Macrophage and Stromal Activation in Rheumatoid Arthritis Pannus. <i>Journal of Nuclear Medicine</i> , 2018, 59, 1125-1132.	2.8	46
98	¹¹ C-DPA-713 has much greater specific binding to translocator protein 18â€‰kDa (TSPO) in human brain than ¹¹ C-(<i>R</i>)-PK11195. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2018, 38, 393-403.	2.4	51
99	In vivo PET imaging of neuroinflammation in Alzheimerâ€™s disease. <i>Journal of Neural Transmission</i> , 2018, 125, 847-867.	1.4	52
100	The Low-Affinity Binding of Second Generation Radiotracers Targeting TSPO is Associated with a Unique Allosteric Binding Site. <i>Journal of NeuroImmune Pharmacology</i> , 2018, 13, 1-5.	2.1	14
101	Impact of Endothelial 18-kDa Translocator Protein on the Quantification of ¹⁸ F-DPA-714. <i>Journal of Nuclear Medicine</i> , 2018, 59, 307-314.	2.8	52
102	Novel potential pyrazolopyrimidine based translocator protein ligands for the evaluation of neuroinflammation with PET. <i>European Journal of Medicinal Chemistry</i> , 2018, 159, 292-306.	2.6	13
103	Advances in PET Methodology. <i>International Review of Neurobiology</i> , 2018, 141, 3-30.	0.9	7
104	PET/CT of Dementia. <i>American Journal of Roentgenology</i> , 2018, 211, 246-259.	1.0	18
105	Imaging Translocator Protein as a Biomarker of Neuroinflammation in Dementia. <i>Advances in Pharmacology</i> , 2018, 82, 163-185.	1.2	32
106	Role of Neuroinflammation in the Trajectory of Alzheimerâ€™s Disease and in vivo Quantification Using PET. <i>Journal of Alzheimer's Disease</i> , 2018, 64, S339-S351.	1.2	32
107	<i>In vivo</i> imaging biomarkers of neuroinflammation in the development and assessment of stroke therapies - towards clinical translation. <i>Theranostics</i> , 2018, 8, 2603-2620.	4.6	36
108	Integrated magnetic resonance imaging and [¹¹ C]â€“PBR28 positron emission tomographic imaging in amyotrophic lateral sclerosis. <i>Annals of Neurology</i> , 2018, 83, 1186-1197.	2.8	75
109	Does inflammation precede tau aggregation in early Alzheimer's disease? A PET study. <i>Neurobiology of Disease</i> , 2018, 117, 211-216.	2.1	46
110	Prospects and challenges of imaging neuroinflammation beyond TSPO in Alzheimerâ€™s disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 2831-2847.	3.3	45

#	ARTICLE	IF	CITATIONS
111	Translocator protein in late stage Alzheimer's disease and Dementia with Lewy bodies brains. <i>Annals of Clinical and Translational Neurology</i> , 2019, 6, 1423-1434.	1.7	22
112	Recent Developments in TSPO PET Imaging as A Biomarker of Neuroinflammation in Neurodegenerative Disorders. <i>International Journal of Molecular Sciences</i> , 2019, 20, 3161.	1.8	173
113	TSPO Ligands Boost Mitochondrial Function and Pregnenolone Synthesis. <i>Journal of Alzheimer's Disease</i> , 2019, 72, 1045-1058.	1.2	38
114	Prostate cancer and inflammation: A new molecular imaging challenge in the era of personalized medicine. <i>Nuclear Medicine and Biology</i> , 2019, 68-69, 66-79.	0.3	19
115	A new perspective for advanced positron emission tomography-based molecular imaging in neurodegenerative proteinopathies. <i>Alzheimer's and Dementia</i> , 2019, 15, 1081-1103.	0.4	16
116	Neuroinflammation and amyloid-beta 40 are associated with reduced serotonin transporter (SERT) activity in a transgenic model of familial Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 38.	3.0	21
117	Confirmation of Specific Binding of the 18-kDa Translocator Protein (TSPO) Radioligand [18F]GE-180: a Blocking Study Using XBD173 in Multiple Sclerosis Normal Appearing White and Grey Matter. <i>Molecular Imaging and Biology</i> , 2019, 21, 935-944.	1.3	32
118	Imaging in Neurodegeneration: Movement Disorders. <i>IEEE Transactions on Radiation and Plasma Medical Sciences</i> , 2019, 3, 262-274.	2.7	4
119	New and Old TSPO PET Radioligands for Imaging Brain Microglial Activation in Neurodegenerative Disease. <i>Current Neurology and Neuroscience Reports</i> , 2019, 19, 24.	2.0	61
120	Detecting neuroinflammation in the brain following chronic alcohol exposure in rats: A comparison between in vivo and in vitro TSPO radioligand binding. <i>European Journal of Neuroscience</i> , 2019, 50, 1831-1842.	1.2	20
121	¹⁸ F-AzaFol for Detection of Folate Receptor-1 ² Positive Macrophages in Experimental Interstitial Lung Disease—A Proof-of-Concept Study. <i>Frontiers in Immunology</i> , 2019, 10, 2724.	2.2	27
122	Brain glial activation in fibromyalgia — A multi-site positron emission tomography investigation. <i>Brain, Behavior, and Immunity</i> , 2019, 75, 72-83.	2.0	186
123	Neuroinflammation and Cytokines in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS): A Critical Review of Research Methods. <i>Frontiers in Neurology</i> , 2018, 9, 1033.	1.1	81
124	<i>In vivo</i> molecular imaging of neuroinflammation in Alzheimer's disease. <i>Journal of Neurochemistry</i> , 2019, 149, 438-451.	2.1	70
125	Concentration, distribution, and influence of aging on the 18-kDa translocator protein in human brain: Implications for brain imaging studies. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2020, 40, 1061-1076.	2.4	13
126	TSPO Versus P2X7 as a Target for Neuroinflammation: An In Vitro and In Vivo Study. <i>Journal of Nuclear Medicine</i> , 2020, 61, 604-607.	2.8	42
127	Rapidly (and Successfully) Translating Novel Brain Radiotracers From Animal Research Into Clinical Use. <i>Frontiers in Neuroscience</i> , 2020, 14, 871.	1.4	7
128	Neuroinflammation in psychiatric disorders: PET imaging and promising new targets. <i>Lancet Psychiatry</i> , 2020, 7, 1064-1074.	3.7	149

#	ARTICLE	IF	CITATIONS
129	Tracing the History of the Human Translocator Protein to Recent Neurodegenerative and Psychiatric Imaging. <i>ACS Chemical Neuroscience</i> , 2020, 11, 2192-2200.	1.7	13
130	Advances in PET to assess pulmonary inflammation: A systematic review. <i>European Journal of Radiology</i> , 2020, 130, 109182.	1.2	10
131	[18F]CB251 PET/MR imaging probe targeting translocator protein (TSPO) independent of its Polymorphism in a Neuroinflammation Model. <i>Theranostics</i> , 2020, 10, 9315-9331.	4.6	15
132	Perspective: Solving the Heterogeneity Conundrum of TSPO PET Imaging in Psychosis. <i>Frontiers in Psychiatry</i> , 2020, 11, 362.	1.3	15
133	Moving Toward Multicenter Therapeutic Trials in Amyotrophic Lateral Sclerosis: Feasibility of Data Pooling Using Different Translocator Protein PET Radioligands. <i>Journal of Nuclear Medicine</i> , 2020, 61, 1621-1627.	2.8	22
134	In-vivo imaging of neuroinflammation in veterans with Gulf War illness. <i>Brain, Behavior, and Immunity</i> , 2020, 87, 498-507.	2.0	80
135	Nondisplaceable Binding Is a Potential Confounding Factor in ¹¹ C-PBR28 Translocator Protein PET Studies. <i>Journal of Nuclear Medicine</i> , 2021, 62, 412-417.	2.8	10
136	An In Vivo Study of a Rat Fluid-Percussion-Induced Traumatic Brain Injury Model with [11C]PBR28 and [18F]flumazenil PET Imaging. <i>International Journal of Molecular Sciences</i> , 2021, 22, 951.	1.8	7
137	PET Imaging of Neuroinflammation. , 2021, , 1335-1371.		3
138	The Interplay of Cholesterol and Ligand Binding in hTSPO from Classical Molecular Dynamics Simulations. <i>Molecules</i> , 2021, 26, 1250.	1.7	5
139	Kinetic modeling and parameter estimation of TSPO PET imaging in the human brain. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 49, 246-256.	3.3	27
140	Preclinical Evaluation of TSPO and MAO-B PET Radiotracers in an LPS Model of Neuroinflammation. <i>PET Clinics</i> , 2021, 16, 233-247.	1.5	15
141	Impact of TSPO Receptor Polymorphism on [18F]GE-180 Binding in Healthy Brain and Pseudo-Reference Regions of Neurooncological and Neurodegenerative Disorders. <i>Life</i> , 2021, 11, 484.	1.1	11
142	Amyloid and Tau Induce Cell Death Independently of TSPO Polymerization and Density Changes. <i>ACS Omega</i> , 2021, 6, 18719-18727.	1.6	2
143	Preclinical evaluation of (S)-[18F]GE387, a novel 18-kDa translocator protein (TSPO) PET radioligand with low binding sensitivity to human polymorphism rs6971. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 49, 125-136.	3.3	11
144	Translation of 11C-labeled tracer synthesis to a CGMP environment as exemplified by [11C]ER176 for PET imaging of human TSPO. <i>Nature Protocols</i> , 2021, 16, 4419-4445.	5.5	7
145	Neuroimmune signatures in chronic low back pain subtypes. <i>Brain</i> , 2022, 145, 1098-1110.	3.7	24
146	Synthesis and pharmacological evaluation of [¹⁸ F]PBR316: a novel PET ligand targeting the translocator protein 18 kDa (TSPO) with low binding sensitivity to human single nucleotide polymorphism rs6971. <i>RSC Medicinal Chemistry</i> , 2021, 12, 1207-1221.	1.7	7

#	ARTICLE	IF	CITATIONS
147	Membrane-embedded TSPO: an NMR view. <i>European Biophysics Journal</i> , 2021, 50, 173-180.	1.2	3
148	[¹⁸ F]DPA-714: Direct Comparison with [¹¹ C]PK11195 in a Model of Cerebral Ischemia in Rats. <i>PLoS ONE</i> , 2013, 8, e56441.	1.1	77
149	The macrophage marker translocator protein (TSPO) is down-regulated on pro-inflammatory α -M1 β ™ human macrophages. <i>PLoS ONE</i> , 2017, 12, e0185767.	1.1	59
150	Considerations in the Development of Reversibly Binding PET Radioligands for Brain Imaging. <i>Current Medicinal Chemistry</i> , 2016, 23, 1818-1869.	1.2	149
151	TSPO PET Imaging as a Biomarker of Neuroinflammation in Neurodegenerative Disorders. <i>Neuroinformatics</i> , 2022, , 407-427.	0.2	2
153	In Vivo Imaging of Neuroinflammation in Acute Brain Injury. , 2014, , 235-248.		0
154	The Impact of Genetic Polymorphisms on Neuroreceptor Imaging. , 2014, , 149-178.		0
155	PET Imaging in Multiple Sclerosis: Focus on the Translocator Protein. , 2014, , 757-773.		1
156	Dementia Due to Neurodegenerative Disease: Molecular Imaging Findings. , 2014, , 185-211.		1
157	Positron-Emission-Tomography Imaging of Long-Term Expression of the 18kDa Translocator Protein After Sudden Cardiac Arrest in Rats. <i>Shock</i> , 2020, Publish Ahead of Print, 620-629.	1.0	4
159	Neuroinflammation: From Target Selection to Preclinical and Clinical Studies. , 2021, , 567-592.		1
161	Synthesis and Screening in Mice of Fluorine-Containing PET Radioligands for TSPO: Discovery of a Promising ¹⁸ F-Labeled Ligand. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 16731-16745.	2.9	15
162	Radiosynthesis and characterization of [¹⁸ F]BS224: a next-generation TSPO PET ligand insensitive to the rs6971 polymorphism. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 49, 110-124.	3.3	13
163	Dopamine and Neuroinflammation in Schizophrenia – Interpreting the Findings from Translocator Protein (18kDa) PET Imaging. <i>Neuropsychiatric Disease and Treatment</i> , 2021, Volume 17, 3345-3357.	1.0	2
164	Synthetic methodologies and PET imaging applications of fluorine-18 radiotracers: a patent review. <i>Expert Opinion on Therapeutic Patents</i> , 2022, 32, 455-473.	2.4	2
165	Characterization of neuroinflammatory positron emission tomography biomarkers in chronic traumatic encephalopathy. <i>Brain Communications</i> , 2022, 4, fcac019.	1.5	3
166	Multimodal Investigation of Neuroinflammation in Aviremic Patients With HIV on Antiretroviral Therapy and HIV Elite Controllers. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2022, 9, .	3.1	5
167	Essential Principles and Recent Progress in the Development of TSPO PET Ligands for Neuroinflammation Imaging. <i>Current Medicinal Chemistry</i> , 2022, 29, 4862-4890.	1.2	9

#	ARTICLE	IF	CITATIONS
168	Positron Emission Tomography in the Neuroimaging of Autism Spectrum Disorder: A Review. <i>Frontiers in Neuroscience</i> , 2022, 16, 806876.	1.4	7
170	Nicotinic Acetylcholine Receptors and Microglia as Therapeutic and Imaging Targets in Alzheimer's Disease. <i>Molecules</i> , 2022, 27, 2780.	1.7	10
171	Beyond monoamines: I. Novel targets and radiotracers for Positron emission tomography imaging in psychiatric disorders. <i>Journal of Neurochemistry</i> , 2023, 164, 364-400.	2.1	7
172	Human pharmacokinetics of XBD173 and etifoxine distinguish their potential for pharmacodynamic effects mediated by TSPO. <i>British Journal of Clinical Pharmacology</i> , 2022, , .	1.1	4
173	[¹⁸ F]BIBD-239: ¹⁸ F-Labeled ER176, a Positron Emission Tomography Tracer Specific for the Translocator Protein. <i>Molecular Pharmaceutics</i> , 2022, 19, 2351-2366.	2.3	5
175	Cerenkov luminescence imaging of interscapular brown adipose tissue using a TSPO-targeting PET probe in the UCP1 ThermoMouse. <i>Theranostics</i> , 2022, 12, 6380-6394.	4.6	3
176	Positron Emission Tomography in the Neuroimaging of Autism Spectrum Disorder. , 0, , .		0
177	Evaluation of (R)-[¹¹ C]PK11195 PET/MRI for Spinal Cord-Related Neuropathic Pain in Patients with Cervical Spinal Disorders. <i>Journal of Clinical Medicine</i> , 2023, 12, 116.	1.0	3
178	Assessing the potential anti-neuroinflammatory effect of minocycline in chronic low back pain: Protocol for a randomized, double-blind, placebo-controlled trial. <i>Contemporary Clinical Trials</i> , 2023, 126, 107087.	0.8	2
179	Molecular Imaging of Neuroinflammation in Alzheimer's Disease and Mild Cognitive Impairment. <i>Advances in Experimental Medicine and Biology</i> , 2023, , 301-326.	0.8	0
180	Inflammatory Immune Process and Depression-like Behavior in Hypothyroid Rats: A [¹⁸ F] DPA-714 Micro Positron Emission Tomography Study. <i>Pharmaceutics</i> , 2023, 16, 279.	1.7	1